Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5962468 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(8 years ago) | |
US5633262 | LG CHEM LTD | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(8 years ago) | |
US5776944 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(7 years ago) | |
US6723734 | LG CHEM LTD | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(6 years ago) | |
US6340689 | LG CHEM LTD | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(4 years ago) | |
US6803376 | LG CHEM LTD | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(4 years ago) | |
US6455540 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(4 years ago) | |
US6331550 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(4 years ago) | |
US6262071 | LG CHEM LTD | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(4 years ago) |
Factive is owned by Lg Chem Ltd.
Factive contains Gemifloxacin Mesylate.
Factive has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Factive are:
Factive was authorised for market use on 04 April, 2003.
Factive is available in tablet;oral dosage forms.
Factive can be used as use of quinolone compounds against pneumococcal pathogenic bacteria, method of treating bacterial infections, use of quinolone compounds against atypical upper respiratory pathogenic bacteria, methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria, use of quinolone compounds against anaerobic pathogenic bacteria.
The generics of Factive are possible to be released after 21 September, 2019.
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Treatment: Method of treating bacterial infections; Use of quinolone compounds against atypical upper respiratory pathogenic bacteria; Use of quinolone compounds against pneumococcal pathogenic bacteria; Use of ...
Dosage: TABLET;ORAL